Embedded World: GigaDevice Showcases Advances in Flash and MCU Technologies for Edge AI, Green Energy, Automotive and IOT

10.3.2025 09:00:00 CET | Business Wire | Press Release

GigaDevice, a leading semiconductor company specializing in flash memory, 32-bit microcontrollers (MCUs), sensors, analog products and solutions, has announced it will attend Embedded World and showcase its latest advances in flash and MCU technologies.

At the show, the company will demonstrate both the resilience and the adaptability of its solutions across four strategically important yet diverse applications: edge AI, industrial and green energy, automotive, and connectivity.

Taking place in Nuremberg, Germany from the 11^th of March, Embedded World is among the world’s leading symposiums for developers and architects of embedded systems. GigaDevice’s main stand is located in Hall 5, Stand 5-129.

Transform Edge AI with Smarter Solutions

AI algorithms for a GD32H7 MCU-based neural net AFCI

GigaDevice’s advanced Arc Fault Circuit Interrupter (AFCI) technology enables electrical safety in commercial and industrial settings by detecting dangerous arc faults in real time, preventing electrical fires. The demo, based on the GD32H7 with a 500K sampling rate and 12 ADC channels for real-time AI inference, utilizes a deep convolutional neural network processing 4,096 sampling points. It showcases precise detection of abnormal arcing while distinguishing harmless operations. Compatible with various hardware, the model enables one-click training for edge AI in adaptive function compute infrastructure. With cutting-edge detection and intelligent protection, GigaDevice reaffirms its commitment to electrical safety innovation.

Keyword Recognition: Offline AI Solution for GD32W515 with Customizable Training and Minimal Memory Usage

GigaDevice’s offline keyword-recognition solution, built on the GD32W515 reference design, utilizes an optimized AI algorithm that ensures minimal memory usage while delivering high-performance results. Companion software is also under development to allow the easy customization of keywords, and the ability to retrain it in less than 24 hours. The solution supports both training with and without target voice samples, offering flexibility for a wide range of applications. Additionally, the company is developing an online keyword detection feature for the GD32W515, which will further enhance its capabilities.

Optimize Industrial Processes with Green Energy Innovation

Real-time motion control in industrial and green energy systems

The GD32H75E enables real-time EtherCAT servo control for industrial automation, supporting the CiA 402 protocol and seamless TwinCAT integration. It delivers precise motion control through Profile Position mode (PP), 30 origin return Homing Modes (HM), and Cyclic Synchronous Position mode (CSP), with trapezoidal trajectory planning for smooth motion and zero-backlash modes for precise homing.

Bi-directional energy storage inverter

GigaDevice has created a bi-directional energy storage inverter based on its GD32G553 MCU. This system enables energy flow between batteries and the grid for enhanced power stability. It features a modular design with two MCUs controlling the three-layer (LLC, Buck/Boost, and inverter/PFC) architecture.

Boost Automotive Performance with Powerful Electronics

Serial NOR Flash for Automotive applications

GigaDevice’s GD25/55 family of serial NOR flash has been certified to meet ISO 26262:2018 ASIL D automotive functional safety standards and strictly adheres to AEC-Q100 Grade 1. This 2 Mb to 2 Gb capacity flash memory offers 1-, 2-, 4- and 8-channel communication modes and a data throughput rate of 400 MB/s - creating high-quality products to meet strict automotive application requirements.

GigaDevice's second-generation GD32A7 series automotive MCUs, built on an ultra-high-performance Arm® Cortex®-M7 core, offer enhanced computing power, security, and rich peripherals for applications such as body domain control, telematics, lighting, and battery management. Multiple demonstrations based on GD32A7 will be visible on stand, which includes secure communication, BDC, BMS and ADB.

Seamless smart home and IoT connectivity

GigaDevice’s GD32VW553 Matter solution utilizes a high-performance RISC-V core at 160MHz to enable seamless and secure data transmission in complex smart home and IoT applications. With support for Wi-Fi 6 (802.11 b/g/n/ax) and Bluetooth LE 5.2, the evaluation board integrates securely into Matter ecosystems, allowing devices to be controlled via the Tuya Smart App.

Embedded World Exhibitor Forum

GigaDevice will take place in two exhibitor forums on Wednesday 12^th March at Hall 5, Stand-210

14:30-15:00 Emerging Applications with New GigaDevice’s Flash Memory Products by Conrado Canio

15:00-15:30 In-field provisioning and life cycle management for microcontrollers in the era of CRA by Ren Sun (GigaDevice) and Gordon Fairley (Kudelski).

To find out more, please visit the GigaDevice website at www.gigadevice.com, or come to the GigaDevice stand in person – Hall 5, Stand 5-129.

About GigaDevice

GigaDevice Semiconductor Inc. (SSE Stock Code 603986) is a global leading fabless supplier. The company was founded in April 2005 and headquartered in Beijing, China, with branch offices in many countries and regions worldwide, providing local support at customers' fingertips.

Committed to building a complete ecosystem with four major product lines – Flash memory, MCU, sensor and analog – as the core driving force, GigaDevice can provide a wide range of solutions and services in the fields of industrial, automotive, computing, consumer electronics, IoT, mobile, networking and communications. GigaDevice has received the ISO26262:2018 automotive functional safety ASIL D certification, IEC 61508 functional safety production certification, as well as ISO9001, ISO14001, ISO45001, and Duns certifications. In a constant quest to expand our technology offering to customers, GigaDevice has also formed strategic alliances with leading foundries, assembly, and test plants to streamline supply chain management. For more details, please visit: www.gigadevice.com

*GigaDevice and their logos are trademarks, or registered trademarks of GigaDevice Semiconductor Inc. Other names and brands are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250310619865/en/

Contacts

Phone number: + 86 (010) 8288 1196
Email address: marcom@gigadevice.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom